Skip to main content
SpringerLink
Log in

Prediction of Human Pharmacokinetics Based on Preclinical In Vitro and In Vivo Data

  • Conference paper
Pharmacokinetic Challenges in Drug Discovery

Part of the book series: Ernst Schering Research Foundation Workshop ((SCHERING FOUND,volume 37))

Abstract

During the drug discovery process, candidate compounds are screened for their main drug metabolism and pharmacokinetic (DMPK) properties (absorption, distribution, metabolic stability, excretion) to assess their potential to become new drug products. Prentis observed that, of 247 new chemical entities which were withdrawn from drug development before 1985, 198 (80%) failed because of inappropriate pharmacokinetics (Prentis et al. 1988). Kennedy confirmed this conclusion in 1997 by reporting that, apart from a lack of efficacy, poor pharmacokinetic properties were still the main reason for terminating the development of drug candidates (Kennedy 1997). Nowadays, the drop out rate because of pharmacokinetic reasons has probably decreased because DMPK issues are being considered in the discovery process. Therefore, approaches to predict human pharmacokinetic profiles are highly desirable to help select the best candidates for development and/or to reject those with a low probability of success. This can drastically reduce the time and expense of drug development (Norris et al. 2000). Since drug discovery has to screen a large number of compounds, the methods used must be capable of predicting the human pharmacokinetics from a limited set of input data.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Arundel PA (1997) A multi-compai rental model generally applicable, to physiologically-based pharmacokinetics. In: The third IFAC symposium. Modeling and control in biomedical systems. The institute of measurement and control, London

    Google Scholar 

  • Bayliss MK, Bell JA, Jenner WN, Park GR, Wilson K (1999) Utility of hepatocytes to model species differences in the metabolism of loxtidine and to predict pharmacokinetic parameters in rat, dog and man. Xenobiotica 29: 253–268

    Article  PubMed  CAS  Google Scholar 

  • Bernareggi A, Rowland M (1991) Physiologic modeling of cyclosporin kinetics in rat and man. J Pharmacokinet Biopharm 19: 21–50

    PubMed  CAS  Google Scholar 

  • Boxenbaum H (1984) Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm. Drug Metab Rev 15: 1071–1121

    Article  PubMed  CAS  Google Scholar 

  • Boxenbaum H, Fertig JB (1984) Scaling of antipyrine intrinsic clearance of unbound drug in 15 mammalian species. Eur J Drug Metab Pharmacokinet 9: 177–183

    Article  PubMed  CAS  Google Scholar 

  • Boxenbaum B, D’ Souza RW (1990) Interspecies pharmacokinetic scaling, biological design and neoteny. In: Testa B (ed) Advances in drug research. Academic Press, London, pp 139–196

    Google Scholar 

  • Boxenbaum H, Dilea C (1995) First-time-in-human dose selection: Allometric thoughts and perspectives. J Clin Pharmacol 35: 957–966

    Google Scholar 

  • Campbell DB (1994) Can allometric interspecies scaling be used to predict human kinetics. Drug Inf J 28: 235–245

    Article  Google Scholar 

  • Carlile DJ, Zomorodi K, Houston JB (1997) Scaling factors to relate drug metabolic clearance in hepatic microsomes, isolated hepatocytes, and the intact liver: Studies with induced livers involving diazepam. Drug Metab Dispos 25: 903–911

    Google Scholar 

  • Cross DM, Bayliss MK (2000) A commentary on the use of hepatocytes in drug metabolism studies during drug discovery and development. Drug Met Rev 32: 219–240

    Article  CAS  Google Scholar 

  • Houston JB (1994a) Relevance of in vitro kinetic parameters to in vivo metabolism of xenobiotics. Toxicol In Vitro 8: 507–512

    Article  PubMed  CAS  Google Scholar 

  • Houston JB (1994b) Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 47: 1469–1479

    Article  PubMed  CAS  Google Scholar 

  • Houston JB, Carlile DJ (1997) Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. Drug Met Rev 29: 891–922

    Article  CAS  Google Scholar 

  • Iwatsubo T, Hirota N, Ooie T, Suzuki H, Sugiyama Y (1996) Prediction of in vivo drug disposition from in vitro data based on physiological pharmacokinetics. Biopharm Drug Dispos 17: 273–310

    Article  PubMed  CAS  Google Scholar 

  • Iwatsubo T, Suzuki H, Shimada N, Chiba K, Ishizaki T, Green CE, Tyson CA, Yokoi T, Kamataki T, Sugiyama Y (1997) Prediction of in vivo hepatic metabolic clearance of YM796 from in vitro data by use of human liver microsomes and recombinant P-450 isozymes. J Pharmacol Exp Ther 282: 909–919

    PubMed  CAS  Google Scholar 

  • Izumi T, Enomoto S, Hosiyama K, Sasahara K, Shibukawa A, Nakagawa T, Sugiyama Y (1996) Prediction of the human pharmacokinetics of troglitazone, a new and extensively metabolized antidiabetic agent, after oral administration, with an animal scale-up approach. J Pharmacol Exp Ther 277: 1630–1641

    PubMed  CAS  Google Scholar 

  • Kennedy T (1997) Managing the drug discovery/development interface. Drug Discovery Today 2: 436–444

    Article  Google Scholar 

  • Lave T, Coassolo P (1998) Commentary on “integration of in vitro data and brain weight in allometric scaling to predict clearance in humans: Some suggestions”. J Pharm Sci 87: 530

    Google Scholar 

  • Lave T, Coassolo P, Reigner B (1999a) Prediction of hepatic metabolic clearance based on interspecies allometric scaling techniques and in vitro-in vivo correlations. Clin Pharmacokinet 36: 211–231

    Article  PubMed  CAS  Google Scholar 

  • Lave T, Levettrafit B, Schmitthoffmann AH, Morgenroth B, Richter W, Chou RC (1995) Interspecies Scaling of Interferon Disposition and Comparison of Allometric Scaling With Concentration-Time Transformations. J Pharm Sci 84: 1285–1290

    Article  PubMed  CAS  Google Scholar 

  • Lave T, Dupin S, Schmitt C, Chou RC, Jaeck D, Coassolo P (1997a) Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: Application to 10 extensively metabolized drugs. J Pharm Sci 86: 584–590

    Article  PubMed  CAS  Google Scholar 

  • Lave T, Saner A, Coassolo P, Brandt R, Schmitt Hoffmann AH, Chou RC (1996a) Animal pharmacokinetics and interspecies scaling from animals to man of lamifiban, a new platelet aggregation inhibitor. J Pharm Pharmacol 48: 573–577

    Article  PubMed  CAS  Google Scholar 

  • Lave T, Portmann R, Schenker G, Gianni A, Guenzi A, Girometta MA, Schmitt M (1999b) Interspecies pharmacokinetic comparisons and allometric scaling of napsagatran, a low molecular weight thrombin inhibitor. J Pharm Pharmacol 51: 85–91

    Article  PubMed  CAS  Google Scholar 

  • Lave T, Coassolo P, Ubeaud G, Brandt R, Schmitt C, Dupin S, Jaeck D, Chou RC (1996b) Interspecies scaling of bosentan, a new endothelin receptor antagonist and integration of in-vitro data into allometric scaling. Pharmaceut Res 13: 97–101

    Article  CAS  Google Scholar 

  • Lave T, Dupin S, Schmitt C, Valles B, Ubeaud G, Chou RC, Jaeck D, Coassolo P (1997b) The use of human hepatocytes to select compounds based on their expected hepatic extraction ratios in humans Pharmaceut Res 14: 152–155

    CAS  Google Scholar 

  • Lave T, Schmitt-Hoffmann AH, Coassolo P, Ubeaud G, Vallès B, Ba B, Brandt R, Chou RC (1995b) A new extrapolation method from animal to man; application to a metabolized compound, mofarotene. Life Sci 56: 473–478

    Article  Google Scholar 

  • Lave T, Dupin S, Schmitt M, Kapps M, Meyer J, Morgenroth B, Chou RC, Jaeck D, Coassolo P (1996c) Interspecies scaling of tolcapone, a new inhibitor of catechol-0- methyltransferase ( COMT) Use of in vitro data from hepatocytes to predict metabolic clearance in animals and humans. Xenobiotica 26: 839–851

    Google Scholar 

  • Lin JH (1998) Applications and limitations of interspecies scaling and in vitro extrapolation in pharmacokinetics. Drug Metab Dispos 26: 1202–1212

    PubMed  CAS  Google Scholar 

  • Lin JH, Sugiyama Y, Awazu S, Hanano M (1982) Physiological pharmacokinetics of ethoxybenzamide based on biochemical data obtained in vitro as well as on physiological data. J Pharmacol Exp Ther 10: 649–661

    CAS  Google Scholar 

  • Mordenti J (1985) Pharmacokinetic scale-up: accurate prediction of human pharmacokinetic profiles from animal data. J Pharm Sci 74: 1097–1099

    Article  PubMed  CAS  Google Scholar 

  • Mordenti J (1986) Man versus beast: pharmacokinetic scaling in mammals. J Pharm Sci 75: 1028–1040

    Article  PubMed  CAS  Google Scholar 

  • Norris DA, Leesman GD, Sinko PJ, Grass GM (2000) Development of predictive pharmacokinetic simulation models for drug discovery. J Control Rel 65: 55–62

    Article  CAS  Google Scholar 

  • Obach RS (1996) The importance of nonspecific binding in in vitro matrices, its impact on enzyme kinetic studies of drug metabolism reactions, and implications for in vitro-in vivo correlations (letter) Drug Metab Dispos 24: 1047–1049

    PubMed  CAS  Google Scholar 

  • Obach RS (1999) Prediction of human clearance of 29 drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27: 1350–1359

    PubMed  CAS  Google Scholar 

  • Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, Maclntyre F, Rance DJ, Wastall P (1997) The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283: 46–58

    PubMed  CAS  Google Scholar 

  • Poulin P, Theil FP (2000) A priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. J Pharm Sci 89: 16–35

    Article  PubMed  CAS  Google Scholar 

  • Poulin P, Schoenlein K, Theil F (2001) Prediction of adipose tissue: Plasma partition coefficients for structurally unrelated drugs. J Pharm Sci 90: 436–447

    Google Scholar 

  • Prentis RA, Lis Y, Walker SR. (1988) Pharmaceutical innovation by the seven UK-owned companies (1964–1985) Br J Clin Pharmacol 25: 387–396

    PubMed  CAS  Google Scholar 

  • Richter WF, Heizmann P, Meyer J, Starke V, Lave T (1998) Animal pharmacokinetics and interspecies scaling of Ro 25–6833 and related (lactamylvinyl)cephalosporins. J Pharm Sci 87: 496–500

    Article  PubMed  CAS  Google Scholar 

  • Schneider G, Coassolo P, Lave T (1999) Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural. networks and multivariate statistical techniques. J Med Chem 42: 5072–5076

    Article  PubMed  CAS  Google Scholar 

  • Schuhmann G, Fichtl B, Kurz H (1987) Prediction of drug distribution in vivo on the basis of in vitro binding data. Biopharm Drug Dispos 8: 73–86

    Article  PubMed  CAS  Google Scholar 

  • Zuegge J, Schneider G, Coassolo P, Lave T (2001) Prediction of hepatic metabolic clearance in man — comparison and assessment of prediction models. Clin Pharmacokinet 40: 553–563

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. T. Lavé
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. O. Luttringer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Zuegge
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Schneider
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P. Coassolo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. F.-P. Theil
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pharmacology and Toxicology, University of Oulu, PL 5000 (Aapistie 5), 90014, Oulu, Finnland

    O. Pelkonen

  2. Research Pharmacokinetics, Schering AG, MĂĽllerstraĂźe 178, 13342, Berlin, Germany

    A. Baumann  & A. Reichel  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Lavé, T., Luttringer, O., Zuegge, J., Schneider, G., Coassolo, P., Theil, FP. (2002). Prediction of Human Pharmacokinetics Based on Preclinical In Vitro and In Vivo Data. In: Pelkonen, O., Baumann, A., Reichel, A. (eds) Pharmacokinetic Challenges in Drug Discovery. Ernst Schering Research Foundation Workshop, vol 37. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-04383-7_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-04383-7_5

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-04385-1

  • Online ISBN: 978-3-662-04383-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation